Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Antibody-drug conjugates (ADCs) company CCO departs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 02, 2022 12:24pm

158 Views

Post# 35066678

RE:RE:RE:RE:RE:RE:Antibody-drug conjugates (ADCs) company CCO departs

October 31, 2022 - Daiichi Sankyo sets new highs for AstraZeneca-partnered ADC cancer drug Enhertu

The Japanese pharma on Monday upped its forecast for Enhertu this year by more than $400 million, projecting it could haul in about $1.3 billion in sales this year.

Daiichi recently noted that Enhertu hit on a primary endpoint for a Phase III postmarket commitment trial after winning approval as a third-line treatment for HER2-positive breast cancer.

https://endpts.com/daiichi-sankyo-sets-new-highs-for-astrazeneca-partnered-cancer-drug-enhertu/

<< Previous

Bullboard Posts

Next >>

This junior mining stock offers billions in market exposure